immatics biotechnologies GmbH Significantly Improves XPRESIDENT(TM) Technology Platform
6/17/2009 11:35:46 AM
More...
|
immatics biotechnologies GmbH Completes Patient Recruitment In Phase II Study With Cancer Vaccine IMA901 For Renal Cell Cancer
3/3/2009 12:53:50 PM
More...
|
immatics biotechnologies GmbH Wins 29th German Industry's Innovation Award
1/26/2009 1:43:03 PM
More...
|
immatics biotechnologies GmbH Obtains Important U.S. and European Patents
7/14/2008 11:38:03 AM
More...
|
immatics biotechnologies GmbH Appoints Paul G. Higham as Chief Executive Officer
7/9/2008 9:09:10 AM
More...
|
immatics biotechnologies GmbH Receives 3 Research Grants Totaling 1.4 mn € to Advance its Early-Stage Cancer Immunotherapy Programs
7/7/2008 1:10:40 PM
More...
|
immatics biotechnologies GmbH Granted Orphan Drug Status for Therapeutic Cancer Vaccine IMA901
3/14/2007 4:36:32 PM
More...
|
immatics biotechnologies GmbH Receives 40 Million Eur In Second Round Of Cancer Treatment Funding
2/8/2007 11:36:21 AM
More...
|
immatics biotechnologies GmbH Succesfully Concludes Phase 1 Clinical Study On Potential Renal Cell Cancer Vaccine
10/10/2006 2:32:14 PM
More...
|
immatics biotechnologies GmbH And responsif GmbH Sign A Cooperation Agreement Within The Scope Of The BioChancePLUS Grant Program
5/22/2006 2:30:07 PM
More...
|